BDD2020 Online Sponsors - Takeda

More information on one of our BDD2020 Online Sponsors.

Since May 1st, 2020, Adcetris is reimbursed for adult patients with Mycosis Fungoides & primary cutaneous Anaplastic Large Cell Lymphoma after 2 failed systemic treatment lines incl. interferon-α, methotrexate and bexarotene, a combination of these or proven intolerance.

Adcetris, the only CD30-targeted therapy, provides cutaneous T-cell lymphoma (CTCL) patients with a new efficacious and durable treatment option.
The Alcanza trial is the 1st randomized and largest reported phase 3 trial, studying Adcetris vs. methotrexate or bexarotene in CTCL patients using the present international consensus response criteria incl. skin, nodal, visceral & blood responses. The trial demonstrated superior results in all endpoints for Adcetris.
Adcetris being an orphan drug, can only be prescribed after a MOC-decision and by hematologists, medical oncologists or dermatologists with experience in treating CTCL. For more information please send an e-mail to

Takeda

View the publication.

Takeda